Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Self-control Trial to Evaluate the Remission Rate in Newly Diagnosed Type 2 Diabetes Patients After Treatment With Insulin Aspart
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- First Posted Date
- 2007-07-02
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 33
- Registration Number
- NCT00494988
Efficacy and Safety of Repaglinide and Metformin Combination Therapy in Type 2 Diabetes Failing on Oral Anti-diabetic Drugs
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 187
- Registration Number
- NCT00491725
Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds
Phase 2
Completed
- Conditions
- Congenital Bleeding DisorderHaemophilia AHaemophilia B
- Interventions
- First Posted Date
- 2007-06-14
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 51
- Registration Number
- NCT00486278
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom
Safety and Effect of Biphasic Insulin Aspart 50 in Patients With Type 2 Diabetes Mellitus.
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2007-05-22
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 81
- Registration Number
- NCT00476437
Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2007-05-16
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 470
- Registration Number
- NCT00474045
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Watford, United Kingdom
Safety of Inhaled Human Insulin in Subjects With Diabetes Mellitus and Chronic Obstructive Pulmonary Disease (COPD)
Phase 3
Terminated
- Conditions
- Chronic Obstructive Pulmonary DiseaseDiabetes Mellitus, Type 2DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2007-05-14
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 38
- Registration Number
- NCT00472953
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Kocaeli, Turkey
Efficacy and Safety of Inhaled Insulin Compared to Metformin and Glimepiride in Type 2 Diabetes
Phase 3
Terminated
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2007-05-04
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 174
- Registration Number
- NCT00469586
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Konya, Turkey
Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes
- Interventions
- First Posted Date
- 2007-05-04
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 480
- Registration Number
- NCT00469092
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Stockholm, Sweden
Efficacy and Safety of 17-Beta Estradiol in Treatment of Atrophic Vaginitis
Phase 3
Completed
- Conditions
- MenopausePostmenopausal Vaginal Atrophy
- First Posted Date
- 2007-04-24
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 230
- Registration Number
- NCT00465192
Evaluation of Safety and Efficacy of 17-Beta Estradiol in Treatment of Atrophic Vaginitis: An Extension Trial
Phase 3
Completed
- Conditions
- Postmenopausal Vaginal AtrophyMenopause
- First Posted Date
- 2007-04-24
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 102
- Registration Number
- NCT00464971
© Copyright 2025. All Rights Reserved by MedPath